+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Abacavir"

Global HIV Drugs Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

Global HIV Drugs Market Analysis & Forecast to 2024-2034

  • Report
  • January 2024
  • 200 Pages
  • Global
From
US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026 - Product Thumbnail Image

US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026

  • Report
  • February 2021
  • 360 Pages
  • United States
From
Tivicay (dolutegravir; ViiV Healthcare) Drug Overview 2019 - Product Thumbnail Image

Tivicay (dolutegravir; ViiV Healthcare) Drug Overview 2019

  • Report
  • June 2019
  • 26 Pages
  • Global
From
  • 11 Results (Page 1 of 1)
Loading Indicator

Abacavir is an immune disorder drug used to treat HIV infection. It is a nucleoside reverse transcriptase inhibitor (NRTI) that works by blocking the action of the enzyme reverse transcriptase, which is needed for the virus to replicate. Abacavir is usually taken in combination with other antiretroviral drugs to help control HIV infection. It is available in both oral and injectable forms. Abacavir is used to treat HIV infection in adults and children over the age of three months. It is also used to reduce the risk of HIV transmission from mother to child during pregnancy and delivery. Abacavir is generally well tolerated, but can cause side effects such as nausea, vomiting, and rash. The abacavir market is highly competitive, with several major players offering products. Some of the leading companies in the market include Gilead Sciences, Bristol-Myers Squibb, Merck & Co., and GlaxoSmithKline. These companies are continuously developing new products and expanding their product portfolios to meet the needs of patients. Show Less Read more